Roy Arya Mariam, Bawek Sawyer, Parikh Richa, Faisal Muhammad Salman, Ghione Paola
Roswell Park Comprehensive Cancer Center Buffalo New York USA.
Department of Hematology/Oncology Karmanos Cancer Institute/Wayne State University Detroit Michigan USA.
EJHaem. 2025 May 6;6(3):e70036. doi: 10.1002/jha2.70036. eCollection 2025 Jun.
Large granular lymphocytic leukemia (LGL) is a rare lymphoproliferative disorder, with limited literature available about the epidemiology, survival, and development of secondary primary malignancies (SPMs) in T-LGL.
The Surveillance, Epidemiology, and End Results (SEER) 17 registry was used to identify all cases of T-LGL diagnosed between 2000 and 2019, and patients with primary T-LGL were analyzed.
Patients with primary T-LGL were found to have a higher incidence of SPMs compared to the general population, with increased risk for hematological malignancies seen within the first 10 years and solid tumors seen after 10 years of T-LGL diagnosis.
Patients with primary T-LGL were found to have a higher incidence of SPMs. Further research is needed to better understand the reason for this increased risk.
The authors have confirmed clinical trial registration is not needed for this submission.
大颗粒淋巴细胞白血病（LGL）是一种罕见的淋巴细胞增殖性疾病，关于T-LGL的流行病学、生存率及继发性原发性恶性肿瘤（SPM）的发生发展的文献有限。
利用监测、流行病学和最终结果（SEER）17登记处来识别2000年至2019年间诊断出的所有T-LGL病例，并对原发性T-LGL患者进行分析。
发现原发性T-LGL患者的SPM发生率高于一般人群，在T-LGL诊断后的前10年内血液系统恶性肿瘤风险增加，10年后实体瘤风险增加。
发现原发性T-LGL患者的SPM发生率较高。需要进一步研究以更好地理解这种风险增加的原因。
作者已确认本提交内容无需临床试验注册。
